# Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

> **NCT07455032** · PHASE1 · RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 22 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **BIOLOGICAL:** intradermal injection of CADI-05
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07455032
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-08
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-01-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07455032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07455032, "Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07455032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*